Studying the Effects of Naloxone-Alum Adjuvant Mixture on Cytokines in Model of Multi- Epitope Vaccine in HIV-1

Subject Areas : Journal of Chemical Health Risks

Meimanat Fathi ¹ ()
Reza Nezamzadeh ² ()
Mehdi Mahdavi ³ ()

Received: 2014-06-14 Accepted : 2018-10-29 Published : 2018-10-29

Keywords:

References:

1. Barouch D.H., Korber B., 2010. HIV-1 vaccine development after STEP. Annual Review of Medicine. 61,153-67.
2. Klein F., Mouquet H., Dosenovic P., Scheid J.F., Scharf L., Nussenzweig M.C., 2013. Antibodies in HIV-1 Vaccine Development and Therapy. Science. 341(6151):1199-204.
3. Aucouturier J., Dupuis L., Ganne V., 2001. Adjuvants designed for veterinary and human vaccines. Vaccine.19(17-19):2666-72.
4. Petrovsky N., Aguilar J.C., 2004.Vaccine adjuvants: Current state and future trends. Immunology and Cell Biology. 82(5): 488-96.
5. Aguilar J.C., Rodríguez E.G., 2007. Vaccine adjuvants revisited. Vaccine. 25(19):3752-62.
6. Lima K.M., dos Santos S.A., Rodrigues J.J., Silva C.L., 2004.Vaccine adjuvant: it makes the difference. Vaccine. 22(19): 2374-9.
7. Mbow M.L., De Gregorio E., Ulmer J.B., 2011. Alum's adjuvant action: grease is the word. Nature Medicine.17(4):415ââ‚‌“6.
8. Tomljenovic L., Shaw C.A., 2011. Aluminum vaccine adjuvants: are they safe? Current Medicinal Chemistry.18(17):2630-7.
9. Lindblad E.B., 2004. Aluminium compounds for use in vaccines. Immunology and Cell Biology. 82(5):497ââ‚‌“505.
10. Jamali A., Mahdavi M., Hassan Z.M., Sabahi F., Farsani M.J., Bamdad, 2009. A novel adjuvant, the general opioid antagonist naloxone, elicits a robust cellular immune response for a DNA vaccine. International Immunology. 21(3): 217-25.
11. Jamali A., Mahdavi M., Shahabi S., Hassan Z.M., Sabahi F., Javan M., 2007. Naloxone, an opioid receptor antagonist, enhances induction of protective immunity against HSV-1 infection in BALB/c mice. Microbial Pathogenesis.43(5-6): 217ââ‚‌“23.
12. Jazani N.H., Sohrabpour M., Mazloomi E., Shahabi S., 2011. A novel adjuvant, a mixture of alum and the general opioid antagonist naloxone, elicits both humoral and cellular immune responses for heat-killed Salmonella typhimurium vaccine. FEMS Immunology and Medical Microbiology. 61(1):54ââ‚‌“62.
13. Jazani N.H., Karimzad M., Mazloomi E., Sohrabpour M., Hassan Z.M., Ghasemnejad H., 2010. Evaluation of the adjuvant activity of naloxone, an opioid receptor antagonist, in combination with heat-killed Listeria monocytogenes vaccine. Microbes and Infection.12(5): 382ââ‚‌“8.
14. Jazani N.H., Parsania S., Sohrabpour M., Mazloomi E., Karimzad M., Shahabi S., 2011. Naloxone and alum synergistically augment adjuvant activities of each other in a mouse vaccine model of Salmonella typhimurium infection. Immunobiology. 216(6): 744ââ‚‌“51.
15. Xu Y.F., Fu L.L., Jiang C.H., Qin Y.W., Ni Y.Q., Fan J.W., 2012. Naloxone Inhibition of Lipopolysaccharide-Induced Activation of Retinal Microglia is Partly Mediated via the p38 Mitogen Activated Protein Kinase Signalling Pathway International Medical Research. 40(4): 1438 ââ‚‌“ 48.
16. Tsai R.Y., Tai Y.H., Tzeng J.I., Lin S.L., Shen C.H., Yang C.P., 2009. Ultra-low dose naloxone restores the antinociceptive effect of morphine in pertussis toxinââ‚‌“treated rats and prevents glutamate transporter downregulation by suppressing the p38 mitogen-activated protein kinase signaling pathway. Neuroscience. 159(4):1244ââ‚‌“56.
17. Moore S.F., MacKenzie A.B., 2009. NADPH oxidase NOX2 mediates rapid cellular oxidation following ATP stimulation of endotoxin-primed macrophages. The Journal of Immunology. 183(5):3302-8. Epub 2009/08/22.
18. Lee K., Won H.Y., Bae M.A., Hong J.H., Hwang E.S., 2011. Spontaneous and aging-dependent development of arthritis in NADPH oxidase 2 deficiency through altered differentiation of CD11b+ and Th/Treg cells. Proceedings of the National Academy of Sciences.108(23):ÂÂ‌ÂÂ‌ÂÂ‌ÂÂ‌ÂÂ‌ÂÂ‌9548-53. Epub 2011/05/20.
19. Shebl F.M., Yu K., Landgren O., Goedert J.J., Rabkin C.S., 2012. Increased Levels of Circulating Cytokines with HIV-Related Immunosuppression AIDS Research and Human Retroviruses. 28(8): 809-5.
20. Wijesundara D.K., Jackson R.J., Tscharke D.C., Ranasinghe C., 2013. IL-4 and IL-13 mediated down-regulation of CD8 expression levels can dampen anti-viral CD8+ T cell avidity following HIV-1 recombinant pox viral vaccination. Vaccine. 31(41): 4548ââ‚‌“55.
21. Chevalier M.F., Petitjean G., Dunyach-Rémy C., Didier C., Girard P.M., Manea M.E., 2013. The Th17/Treg Ratio, IL-1RA and sCD14 Levels in Primary HIV Infection Predict the T-cell Activation Set Point in the Absence of Systemic Microbial Translocation PLOS Pathogens. 9(6): e1003453.
22. Pal R., Wang S., Kalyanaraman V.S., Nair B.C., Whitney S., Keen T., 2005. Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate. Med Primatol. 34(5-6): 226-36.